Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$161.52+0.73 (+0.45%)
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis China Quarterly Revenue Growth (% cc) by Quarter
China Quarterly Revenue Growth (% cc) (%)
Novartis China Quarterly Revenue Growth (% cc): 18.0% in Q3 2026, up 21.0 pts from a year earlier.
Latest, Q3 2026
18.0%
Period ended Sep 30, 2026
Change on a year earlier
+21.0 pts
-3.0% in Q3 2025
History
8 quarters
Since Q4 2024
Sources
8
Documents cited below
Where the Q3 2026 figure comes from
“2 billion of sales from China (+25%, +18% cc).”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | China Quarterly Revenue Growth (% cc) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 18.0% | +21.0 pts | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 6.0% | +7.0 pts | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | 8.0% | -11.0 pts | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 19.0% | +12.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | -3.0% | – | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2025 | Jun 30, 2025 | -1.0% | – | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 19.0% | – | Novartis Form 6-K (0001370368-25-000010) ↗ |
| Q4 2024 | Dec 31, 2024 | 7.0% | – | Novartis Form 6-K (0001370368-25-000007) ↗ |
Cite this data
StockData. (2026). Novartis China Quarterly Revenue Growth (% cc) (%), quarterly Q4 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/geo-china-q-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.